Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men

European Journal of Endocrinology

Volumn 156, Issue 2, 2007, Pages 225-231

  Shimon, Ilan ^a,c   Benbassat, Carlos ^a,c   Hadani, Moshe ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; PROLACTIN; TESTOSTERONE; ANTINEOPLASTIC AGENT; ERGOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADRENAL DISEASE; ADULT; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TRANSSPHENOIDAL SURGERY; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL SYSTEM EXAMINATION; BLOOD; FOLLOW UP; HYPOPHYSIS TUMOR; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME; VISUAL DISORDER; VISUAL FIELD;

ADULT; ANTINEOPLASTIC AGENTS; ERGOLINES; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS; VISUAL FIELDS;

EID: 33947732357     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0646     Document Type: Article

References (26)

1. Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow up. Journal of Neurosurgery 2002 97 299-306.
2. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA & Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003 58 662-670.
3. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J & Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism 1985 60 698-705.
4. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrinology Review 1992 13 220-240.
5. Kleinberg DL, Boyd AE III, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T & Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. New England Journal of Medicine 1983 309 704-709.
6. Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA & Molitch ME. Treatment of prolactin-secreting pituitary macro-adenomas with the long-acting non-ergot dopamine agonist CV 205-502. Annals of Internal Medicine 1990 112 668-673.
7. Webster I, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinernic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine 1994 331 904-909.
8. Biller BM, Molitch ME, Vance ML, Cannistaro KB, Davis KR, Simons JA, Schoenfelder JR & Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism 1996 81 2338-2343.
9. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L & Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinorna shrinkage. Journal of Clinical Endocrinology and Metabolism 1997 82 3574-3579.
10. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2518-2522.
11. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S & Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism 2004 89 1704-1711.
12. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo GF, Merola B, Armunziatc, L & Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883.
13. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Review 2006 27 485-534.
14. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003 6 19-27.
15. Ciric I, Mikhael M, Stafford T, Lawson L & Garces R. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. Journal of Neurosurgery 1983 59 395-401.
16. Davis JR, Sheppard MC & Reath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Quarterly Journal of Medicine 1990 74 227-238.
17. Oruckaptan HH, Semnevsim O, Ozcan OE & Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of literature. Surgical Neurology 2000 53 211-219.
18. Symon L, Jakubowski J & Kendall B. Surgical treatment of giant pituitary adenomas. Journal of Neurology Neurosurgery and Psychiatry 1979 42 973-982.
19. Pia HW, Grote E & Hildebrandt G. Giant pituitary adenomas. Neurosurgery Review 1985 8 207-220.
20. Saeki N, Nakamura M, Sunami K & Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal 1998 45 529-537.
21. Minniti G, Jaffarin-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R & Cantore G. Giant prolactinomas presenting as skull base tumors. Surgical Neurology 2002 57 99-103.
22. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A. Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 500-509.
23. Caccavelli L, Cussac D, Pellegrini I, Audinot V, Jaqut P & Enjalbert A. D2 dopaminergic receptors: normal and abnormal transduction mechanisms. Hormone Research 1992 38 78-83.
24. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR & MacFarlane LA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clinical Endocrinology 2002 52 43-49.
25. Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R, Shing M, Ludolph A & Schuler P. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurologica Scandinavica 2006 113 18-24.
26. Pinero A, Marcos-Alberca P & Fortes J. Cabergoline-related severe restrictive mitral regurgitation. New England Journal of Medicine 1997 337 581-588.